

Madden, David

**Working Paper**

## Covid-19 related excess mortality: An analysis by age for selected countries

UCD Centre for Economic Research Working Paper Series, No. WP25/26

**Provided in Cooperation with:**

UCD School of Economics, University College Dublin (UCD)

*Suggested Citation:* Madden, David (2025) : Covid-19 related excess mortality: An analysis by age for selected countries, UCD Centre for Economic Research Working Paper Series, No. WP25/26, University College Dublin, UCD School of Economics, Dublin

This Version is available at:

<https://hdl.handle.net/10419/337168>

**Standard-Nutzungsbedingungen:**

Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Zwecken und zum Privatgebrauch gespeichert und kopiert werden.

Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich machen, vertreiben oder anderweitig nutzen.

Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, gelten abweichend von diesen Nutzungsbedingungen die in der dort genannten Lizenz gewährten Nutzungsrechte.

**Terms of use:**

*Documents in EconStor may be saved and copied for your personal and scholarly purposes.*

*You are not to copy documents for public or commercial purposes, to exhibit the documents publicly, to make them publicly available on the internet, or to distribute or otherwise use the documents in public.*

*If the documents have been made available under an Open Content Licence (especially Creative Commons Licences), you may exercise further usage rights as specified in the indicated licence.*

*UCD CENTRE FOR ECONOMIC RESEARCH*  
*WORKING PAPER SERIES*  
*2025*

*SRAITH PÁIPÉAR OIBRE AN IONAI*  
*UM THAIGHDE EACNAMAÍOCHTA COBÁC*  
*2025*

**Covid-19 Related Excess Mortality: An Analysis by Age for Selected Countries**

David Madden  
University College Dublin

WP25/26

November 2025

**UCD SCHOOL OF ECONOMICS**  
**UNIVERSITY COLLEGE DUBLIN**

**SCOIL NA HEACNAMAÍOCHTA COBÁC**  
**COLÁISTE NA HOLLSCOILE**  
**BAILE ÁTHA CLIATH**

**BELFIELD**  
**DUBLIN 4**

# **Covid-19 Related Excess Mortality: An Analysis by Age for Selected Countries**

**David Madden**

**(University College Dublin)**

**November 2025**

**Abstract:** This paper analyses excess mortality data for a selection of countries during the Covid period of 2020-2022 using the Short Term Mortality Fluctuations dataset. Adjustments are made to apply a standardised age distribution on the data to obtain age-adjusted excess mortality and this is compared to crude excess mortality data. The adjustment makes a significant difference for some countries but the overall ranking of countries in terms of excess mortality changes very little. This is also the case when years of lost life is used as the mortality metric. The excess mortality data is then correlated with GDP per capita and the Gini coefficient. Excess mortality is negatively correlated with GDP per capita for values of GDP per capita below the median. There is no statistically significant relationship with the Gini coefficient. Cluster analysis suggests distinct clusterings of countries with similar outcomes, particularly the former planned economies of central and eastern Europe.

**Keywords:** Age specific mortality; years of life lost; hierarchical cluster analysis.

**JEL Codes:** I10; I18; J11.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

# **Covid-19 Related Excess Mortality: An Analysis by Age for Selected Countries**

## **Introduction**

The Covid-19 pandemic started in China in November 2019, with the first large outbreak observed in Wuhan in December. Over the following months it spread to most of the world and in March 2020 the World Health Organisation (WHO) declared it a pandemic i.e. the widespread transmission of an infectious disease over a large region of the world. Most countries responded to the arrival of Covid with various public health measures, including orders to “stay at home”, curtailment of public transport and other measures to reduce the spread of disease, measures which came to be known by the general phrase “lockdown”.

The severity of lockdown varied by country (e.g. Sweden notably introduced fewer restrictions) and also by time, in that when case numbers started to fall in early summer 2020 many of the restrictions were lifted. There were subsequent waves of Covid, mostly associated with the arrival of new variants, in nearly all cases more transmissible than earlier variants and in some cases with higher fatality rates, and in many countries restrictive measures were re-introduced. At the same time however, vaccines were developed with remarkable speed. These vaccines either prevented infection (though not transmission) or at least ensured that conditional on being infected, survival rates were considerably higher. There were also breakthroughs in treatments like Paxlovid. By around mid-2022 lockdown measures had been greatly eased in many countries and there was a sense by end-2022 that the worst of the pandemic was “over”.<sup>1</sup>

In this paper, we look at measures of excess mortality over the “Covid period”, defined as from the start of 2020 to the end of 2022. Intuitively, excess mortality is the difference between actual mortality and a measure of projected mortality, where projected mortality is the

---

<sup>1</sup> Arguably, it is incorrect to regard the pandemic as over, given that there are still cases of infections and mortality but one “official” indication that some sort of turning point had been reached was the statement by the WHO in May 2023 that Covid had changed from being a public health emergency to now being an ongoing public health issue. For a comprehensive source on Covid related issues, see [https://www.who.int/health-topics/coronavirus#tab=tab\\_1](https://www.who.int/health-topics/coronavirus#tab=tab_1).

counterfactual of what mortality would have been in the absence of unexpected events, such as Covid. As explained in more detail below, this measure has the advantage of not just taking account of higher mortality arising directly from Covid, but also of taking account of changes in mortality which *indirectly* arise from Covid e.g. due to delayed diagnosis and treatment of other causes, or fewer traffic related accidents etc.

In section 2 of the paper we discuss how to measure excess mortality in more detail and review and compare the principal estimates available. Our principal aim is to examine excess mortality on an age-adjusted basis and how it varies by age group and by country. This means having to choose a specific estimate of excess mortality and this is covered in section 2.

In section 3 we review excess mortality for all ages and then look more closely at mortality rates by specific ages. As fatality rates differ substantially by age, part of the difference between countries overall mortality rates may be explained by the different age structure of the population. We therefore examine what excess mortality rates for our selection of countries would have been if they had all had a “standard” age structure and compare the rankings of countries by crude excess mortality and age adjusted excess mortality.

In section 4 we examine a different measure of mortality, years of life lost and we also analyse age specific mortality rates. Section 5 investigates how age adjusted excess mortality rates varied with measures such as GDP per head and within country inequality and we also apply hierarchical cluster analysis to see if distinct clusterings of countries can be identified. Section 6 presents concluding remarks.

## **2. Excess Mortality**

The use of excess mortality statistics as a means of monitoring mortality from Covid 19 arose from a general dissatisfaction with the use of conventional statistics on cause of death.<sup>2</sup> This can occur owing to problems with diagnosis and cause-of-death coding as well as interactions with pre-existing conditions, such as cardiovascular problems (Shkolnikov et al, 2022). Such

---

<sup>2</sup> This applies not just to Covid 19 but also other infections such as influenza.

interactions can complicate the classification of cause of death, as it could reasonably be attributed to a pre-existing condition or Covid.

Owing to these limitations, all-cause excess mortality is now widely used as a metric of mortality from the pandemic. It compares weekly or monthly specific death rates over a period of time with some projected mortality level. Quite how to calculate this projected mortality level is a modelling choice and discussed in more detail below. Given projected mortality however, excess deaths can then be expressed as

$$\textit{Excess deaths} = \textit{Reported deaths} - \textit{Projected deaths}.$$

They can also be expressed via P-scores, which are more comparable across countries as they take account of different underlying population sizes:

$$P - score = \frac{\textit{Reported deaths} - \textit{Projected deaths}}{\textit{Projected deaths}}.$$

Karlinsky and Kobak (2021), henceforth KK, provide a very useful conceptual breakdown of excess mortality for the Covid 19 period:

Excess Mortality = (A) Deaths caused directly by Covid  
+ (B) Deaths caused by medical system failures due to Covid  
+ (C) Excess Deaths from Other Natural Causes  
+ (D) Excess Deaths from Unnatural Causes  
+ (E) Excess Deaths from Extreme Causes (wars, heatwaves etc).

Factor (B) may arise if services for other conditions are under-resourced, thereby resulting in higher mortality. The contribution of factor (C) may in some cases be negative. For example, if preventative Covid measures also reduce the transmission of other infectious diseases such as influenza, then excess deaths from these diseases could be negative (e.g. Kung et al, 2021). Factor (D) includes mortality arising from traffic accidents, homicides, suicides and drug overdoses and accidents.<sup>3</sup> Factor (E) is not an issue for many countries. For those analysed

---

<sup>3</sup> See Faust et al, 2021, for an analysis of these issues for the US for the March-August 2020 period.

here, the effect of the August 2020 heatwave in Europe is explicitly accounted for in the numbers used.

KK speculate that (C) is likely to be negative, while D and B are both small (for developed countries at least), suggesting that excess mortality is likely to provide a reasonable lower-bound to “true” Covid deaths.

Nepomuceno et al (2022) discuss the sensitivity of excess deaths to a number of different assumptions/choices made: these include the choice of mortality index (absolute or relative), how to calculate projected deaths, the number of years included in the reference period from which projected deaths are calculated and the time unit of the death data. We now discuss each of these in turn.

#### *Choice of Mortality Index*

The choice of mortality index boils down to whether mortality is expressed in terms of actual numbers, or in terms of rates with respect to some underlying base e.g. in the formulation above they are expressed with respect to projected deaths, but they could also be expressed with respect to population. The use of projected deaths as the base takes account of the age structure of the population, unlike the use of the crude population. For example, Msemburi et al (2023) point out that in 2019 both Germany and Iran had similar populations, around 83 million. Mortality in Germany was around 2.5 times higher however, as Germany has an older population with many more people aged over 65. We accordingly present our results below initially with respect to crude underlying population, but then relative to a standardised age distribution, thus controlling for age structure. We also present age-specific excess mortality rates for different age groups.

#### *Choice of Model*

The model chosen to calculate projected deaths is arguably the most critical decision to be made. One of the simplest models is a period specific-average model, whereby projected deaths (or more accurately baseline deaths in this case) are simply the average for the previous  $n$  years (values of 3, 5 or 10 would be common). This model may be employed on an overall or age-specific basis and can be augmented with other features. For example, time trends (either overall or age-specific) and/or harmonic terms which take account of seasonality can be added.

More sophisticated models are also possible, including those that explicitly account for the nature of mortality data. Since death is a binary variable (dead or not) it follows a Bernoulli distribution, which in turn can be approximated by a Poisson or Negative Binomial distribution (in conditions where the underlying number of “trials” is large relative to the probability of the event) which in turn can also take account of within year seasonal trends (for example, see the excess mortality estimates produced by the WHO, Msemburi et al, 2023).

Alternative prominent methodologies include the machine-learning approach adopted by *The Economist* (<https://www.economist.com/graphic-detail/2021/05/13/how-we-estimated-the-true-death-toll-of-the-pandemic> ) and the model of The Institute for Health Metrics and Evaluation (IHME) published in *The Lancet* (Wang et al, 2022). Later in this paper, we explain our choice of model and examine how our measures of excess mortality differ from some of the other.

#### *Choice of Reference Period*

The reference period should ideally reflect the circumstances which would have applied in the absence of the pandemic. A short time period, immediately before the pandemic, has the advantage of being up-to-date and can capture recent mortality trends. However, if the time period is too short then it may contain a lot of “noise” which would then be incorporated into projected excess deaths. The typical choice of reference period for calculating excess mortality during the Covid 19 pandemic has been 2015-2019, though in some cases a longer, ten-year period has been chosen, when monthly data are not available.

#### *Time Unit*

The choice of time unit is typically between weekly or monthly, though in some cases only annual data may be available. Weekly data have the advantage of capturing more immediately any sudden change in mortality conditions. Generally, the longer the time unit, the more the data will be smoothed. It may be preferable to have high frequency data which the analyst can choose to smooth if they wish, rather than lower frequency data where the analyst may not know the degree to which it has been artificially smoothed. The data employed in this paper is weekly.

### 3. Estimates of Excess Mortality

The measure of excess mortality chosen here are based on Karlinsky and Kobak (2021). In their original study, they used the *World Mortality Dataset* for their measures of all-cause mortality. In this study however, we use the figures provided in the Human Mortality Database (see HMD and <http://mortality.org>), a joint venture between the University of California, Berkeley, and Max Planck Institute for Demographic Research. They compiled the *Short Term Mortality Fluctuations (STMF)* dataset, which provides weekly data, broken down into five age groups, with starting dates ranging from as early as 1990 in some cases and all the way up to the present (STMF, 2021, Barbieri et al, 2015). Such data are available for 36 countries (we restrict our analysis to a subset of these, since for Iceland, Luxembourg and Estonia some of the cell-sizes for age specific mortality were too small for analysis).

STMF provides data on actual mortality by age for this set of countries. To calculate excess mortality we also need projected deaths, either in absolute terms or via P-scores, and also broken down by age. The P-scores were obtained from Our World in Data based on the methodology outlined in Karlinsky and Kobak (2021).<sup>4</sup> To obtain baseline deaths, they fit the following regression model for each country and age-group:

$$D_{t,Y} = \alpha_t + \beta Y + \epsilon$$

where  $D_{t,Y}$  is deaths observed in week  $t$  of year  $Y$ ,  $\beta$  is the linear slope or trend across years and  $\epsilon$  is an error term which is normally distributed with mean zero and variance,  $\sigma^2$ . This model can capture time trends via  $\beta$  and seasonal fixed effects via  $\alpha_t$ . This model was fitted over the 2015-2019 period and in all cases the  $\beta$  term was statistically significant, showing the presence of a time trend and indicating that a specific period-average approach would not have been appropriate. The countries analysed here all had weekly data and so the model was estimated over 52 weeks. For 2020, when there was a 53<sup>rd</sup> “week” the value for week 52 was used.

---

<sup>4</sup> <https://ourworldindata.org/excess-mortality-covid#excess-mortality-p-scores-by-age-group>

Then the baseline or projected deaths for any given year, say 2020, is  $\widehat{B}_{t=2020} = \widehat{\alpha}_t + \widehat{\beta} \cdot 2020$  and excess deaths for our period under review is then given by

$$\Delta = \sum_{t \geq t_1} (D_{t,2020} - \widehat{B}_{t,2020}) + \sum_{t \geq t_1} (D_{t,2021} - \widehat{B}_{t,2021}) + \sum_{t \geq t_1} (D_{t,2022} - \widehat{B}_{t,2022})$$

and we set  $t_1 =$  week 1 of January in 2020, 2021 and 2022.

On the basis of this approach, starting from week 1 of January 2020, P-scores by age group are available in Our World in Data for a selection of countries. In addition scores were also kindly provided to us by Dmitry Kobak for a small subset of countries which were not included in the Our World in Data website.<sup>5</sup> Therefore in total we have 32 countries for analysis, although for Taiwan we only have data for 2020 and 2021.

Before examining our excess mortality data, we first compare the figures based upon the KK approach with those provided by three other agencies: the WHO, *The Economist* and the IHME, sometimes referred to as *The Lancet* study (Msember et al, 2023, *The Economist*, 2021 and Wang et al, 2022).

As discussed in section 2, the WHO model is based upon a Negative Binomial model, allowing for within year seasonal variation, while *The Economist* uses a machine learning approach. The Lancet study uses an ensemble approach with six different models each fitted separately by location. The first four models were based upon estimating the seasonal pattern of mortality and then estimating the time trend not accounted for by seasonality. Two other models, one based upon a Poisson model with fixed effects for week and year and the other simply using the weekly mortality for 2019, were also estimated and the final estimated of projected deaths was a weighted ensemble with weights derived from how each model performed in an out of sample predictive validity test (the models were estimated on data up to March 2019 and then tested on the March 2019-February 2020 period).

Rather than compare results on a country by country basis, we identified the ten countries from our sample with the highest absolute number of cumulative excess deaths (note that the WHO

---

<sup>5</sup> Australia, Canada, South Korea, Sweden and Taiwan (only for 2020 and 2021).

and IHME results only extend as far as 2021, so we are examining the countries with highest excess mortality by end-2021). These were, in descending order: the United States, Italy, Poland, United Kingdom, Spain, Germany, France, Bulgaria, Czechia and Chile. In figure 1 we present bar charts of cumulative excess mortality, as a fraction of population, so as to enable comparability. Note that this does not take account of age structure. However, that is not important in this case as we are examining the within country variation in excess mortality estimates, based upon our four different models.

Visual inspection confirms that estimates from the IHME are considerably higher than for the other three models. For nine of the ten countries (the only exception is Chile), the IHME estimates are the largest, in some cases e.g. Bulgaria, substantially so. The next highest estimates are from *The Economist*, and then third and fourth highest is shared between WHO and the estimates which we analyse in this paper (KK), though in fairness the differences between all the non-IHME estimates are very small.

The IHME estimates have been the subject of some criticism on the basis that they provide an overestimate of excess mortality. For example Bager et al (2023) criticise the estimates for Denmark (although not included in figure 1, the IHME estimates for 2020-2021 are up to ten times higher than those of the other three models reviewed here). Similarly, Moeti et al (2023) criticise the estimates for Sub-Saharan Africa, again on the basis that they are too high.<sup>6</sup> Given these criticisms it seems best to regard the IHME estimates as an outlier.

In figure 2, we compare estimates for the longer period, 2020-2022 between KK and *The Economist*, the only two models covering this period. Space permits us to include all of our countries in this case, and we present the KK estimates as a fraction of those of *The Economist*. Apart from South Korea, where the KK estimates are marginally higher than *The Economist*, the KK estimates are typically within 80 per cent of those of *The Economist*, the exceptions being Denmark, Finland and Poland.

Overall then, it seems fair to say that the estimates of excess mortality used here for subsequent analysis, those of KK, are of a similar order of magnitude to those produced by WHO and *The*

---

<sup>6</sup> Hay and Murray (2023) reply to these comments on behalf of IHME.

*Economist*, if perhaps at the lower end. In addition, much of our analysis will concentrate on country *rankings*, and such rankings are very similar between the different measures.<sup>7</sup>

#### 4. Age-adjustments of Excess Mortality

We first present results on excess mortality as a fraction of the underlying population using the KK approach. The underlying population figures are taken from the *United Nations World Population Prospects 2024* (United Nations, 2024). As we are looking at cumulative excess mortality over the 2020-2022 period, we use average population over that period as our base.

Figure 3 presents these cumulative excess mortality estimates for our selected countries (note we also include some extra countries where we have overall excess mortality estimates but not by age-group).<sup>8</sup> New Zealand is estimated to have the lowest excess mortality with a *deficit* of actual deaths relative to projected deaths. The highest estimates are for Bulgaria, with excess mortality estimated at 10 per 100 thousand of the population.

Crude figures such as these can be misleading, however, as they do not take account of the fact that countries will differ in age-structure. We therefore calculate excess mortality controlling for age structure, by applying the age-specific mortality rates for each country to a common age distribution. The common age distribution we use is that provided by Eurostat (Pace et al., 2013), who provide a standardised age distribution based upon the EU-27 plus EFTA countries. For the age groups we consider (0-14, 15-64, 65-74, 75-84, >84), the proportions are 0.16, 0.645, 0.105, 0.065 and 0.025 respectively.

In figure 4, we show the age-standardised excess mortality rates for our selected countries and we also show what we label the “age-contribution”, that part of the crude excess mortality which is contributed by the specific age-structure of the country in question. For most of our countries the age-contribution is positive i.e. it added to crude excess mortality and if the country had the standard Eurostat age structure then its crude excess mortality would have been lower. This is perhaps most prominent in the case of Italy. Its crude excess mortality is just

---

<sup>7</sup> In no case does the rank correlation coefficient between any two of the measures fall below 0.98.

<sup>8</sup> These are Brazil, Ireland, Japan, Russia and Taiwan.

over 4 per one hundred thousand. However, if it had the standard Eurostat age structure, *and assuming its age specific excess mortality had been the same*, then excess mortality would have been about a quarter lower. The underlying assumption, highlighted in italics, is critically important. Age-specific mortality rates might not be independent of age structure. For example, if a country has a high fraction of its population, say, over the age of 75, then medical resources and facilities for this age group might be of very high quality, which in turn would presumably bring *down* age specific mortality for that group. This is potentially an important issue, but one beyond the scope of this paper to address.

Of course, age-structure could also reduce crude excess mortality to below what it would have been if a country had the Eurostat standard. For example, Chile recorded crude excess mortality of 3.1 per one hundred thousand, but if its age structure had been the Eurostat standard then its age-specific excess mortality would have resulted in crude excess mortality almost 50 per cent higher at around 4.5.

Still, standardisation has little effect on the rankings of countries in terms of excess mortality. The rank correlation coefficient between crude and standardised excess mortality is around 0.96 and is highly significant.<sup>9</sup>

#### *Age-specific mortality rates*

Next we turn to examine the age-specific mortality rates to see which age groups fared best in which countries (table 1). For a majority of our selected countries cumulative excess mortality in the 0-14 age group was *negative* over the period. This almost certainly reflects averted births. Most mortality in this age group happens at or very shortly after birth (Li et al, 2021). It is plausible that the Covid pandemic led people to defer planned pregnancies, perhaps owing to concerns over the quality of medical support available during a pandemic, or perhaps owing to uncertainty about the effect of Covid on mother and foetus, or simply general uncertainty at the onset and early stages of the pandemic.<sup>10</sup>

---

<sup>9</sup> Figure 5 shows essentially the same information via a scatter plot between crude excess mortality and age adjusted excess mortality.

<sup>10</sup> It is also possible, though unlikely given the age profile of infection and mortality in Covid, that fertility was adversely affected via direct exposure to the virus. In this case, while cumulative excess mortality may be negative this does not arise for any of the reasons discussed in section 2.

Previous pandemics, such as the 1918 H1N1 Flu, and the more recent Ebola and Zika outbreaks have been associated with declines in birth rates nine months after their peaks (Pomar et al, 2022). Pomar et al (2022) investigate the effect of the first wave of Covid on births in 24 European countries, by looking at live births in January 2021 (approximately nine months after the peak of wave 1 of Covid) compared to the average of January 2018-19 and taking account of secular trends and seasonality. They find a drop of over 14 per cent, though there is a partial rebound in March 2021. They find no change in the trend of live births in the early months of the pandemic suggesting little effect arising from direct exposure to Covid. They also find that the reduction in births is greater where medical systems were under strain (as measured by ICU occupancy) and also by duration and severity of lockdown, which in turn of course is likely to be affected by medical system strain. Adelman et al (2023) carried out a similar study for the US, finding a decline in fertility for wave 1 of Covid but this was not replicated in subsequent waves.

On balance, it seems that fertility (and consequently perinatal mortality) was influenced by Covid, but not uniformly by wave. It is possible that fertility initially declined but then rebounded, so that it is difficult to discern an effect on cumulative mortality. We checked how excess mortality for the 0-14 age group varied over 2020-2022. Since Covid cases for the vast majority of countries were not recorded before March 2020, for planned pregnancies before that date and hence for births up to around the end of 2020, Covid should not have been a factor in these decisions. Hence, we would expect excess mortality for 2020 to exceed that for 2021. Yet that is not the case. Only in eight of our selected countries is excess mortality in 2020 higher than in 2021.

So, while there is evidence of a Covid effect on fertility it may simply be too slight to be picked up in our excess mortality figures, figures which of course apply to a much wider age range than that for perinatal mortality. Nevertheless, these factors should be borne in mind when interpreting results by age group.

Table 2 shows rank correlations for cumulative excess mortality by age group and for the overall population. Consistent with the difficulties discussed above in interpreting the 0-14 figures, we see no rank correlation between excess mortality for this group and any other group. For other age groups the correlations are all positive and highly significant, though it is

noticeable that the correlation between the over 85 age groups and younger groups is less than the inter-group correlations for the 15-64, 64-75 and 75-84 age groups. It is outside the scope of this study to investigate the reasons behind this result but it seems plausible that this may reflect differing experiences with respect to mortality rates in nursing homes.

### *Years of life lost (YLL)*

While we have analysed excess mortality figures above by age, when aggregating we have effectively regarded all deaths as “equal”. Whether someone dies aged 20 or 80 it is still regarded as one death. Another potential metric for mortality is “years of life lost”, which we abbreviate to YLL. On average someone aged 20 will presumably have many more potential years of life left compared to someone aged 80. Precisely how many can be obtained from life-tables. The IHME in its Global Burden of Disease (GBD) Study prepared a reference life-table for calculating YLL due to premature mortality (GBD, 2020). For our example above, they calculate that a premature death aged 20 implies a loss of life of approximately 69 years, while a premature death at 80 implies a loss of approximately 13 years. Therefore, in calculating an overall metric of mortality, the death of a 20 year old would have a higher weight ( $69/13=5.3$ ) compared to the death of an 80 year old. It is important to note that this is not an “ethical” weight, suggesting that one age group is in some sense more “worthy” than another. It simply reflects a different metric for mortality.

In this section we apply the GBD life table to calculate YLL for the countries in our sample and examine how the rankings by country differ from the rankings based simply on excess mortality (both unadjusted and age adjusted). If deaths are higher in younger age categories for any given country, then even controlling for the age distribution, this will give higher YLL, relative to where deaths predominantly occur in an older age category.

The GBD life table is reproduced in table 3 for the relevant end-points of our age categories. Note that as we choose the end point of each age category our figures are a lower bound. Take, for example, the 15-64 age group. Life expectancy ranges here from 74 years for a 15 year old to 25.7 for a 65 year old (the GBD life table is in 5 year intervals, so we do not have precise figures for 64, 74, 84 year olds etc). While it seems likely that within that 15-64 year age category most of the excess mortality would have been towards the end of that category, at least some would have been amongst those in their 20s, 30s, 40s and 50s, whose YLL would have been higher. Hence, applying a YLL of 25.7 on *all* excess mortality in that age interval

is imposing a lower bound. However, since information on the distribution of excess mortality *within* our age categories is lacking, we must employ a uniform value of YLL for each category. Our choice of the end-point is the most conservative choice. For our age category of over 85, we choose the YLL for 90 from the GBD life table.<sup>11</sup>

Thus, for each country we multiply excess deaths in that age category by the corresponding YLL to obtain YLL for each category which we then aggregate to obtain overall YLL. However, we need to express this relative to some underlying population. We construct this relevant population by simply multiplying the numbers in each age category for each country by the corresponding YLL to obtain what we term potential YLL. Actual YLL is then expressed relative to that PYLL.

We also calculate YLL with a further age adjustment by applying the Eurostat age distribution to the YLL for each category and also using this age distribution to calculate PYLL. This measure calculates what total YLL would have been with the age-specific YLL numbers adjusted to the Eurostat age distribution. So, if YLL for age category 15-64 for country A was, say, 300000, and this category was, say 62% of population in country A as opposed to 64% for the Eurostat age distribution, then we multiply the 300000 by 1.032 ( $=.64/.62$ ). Applying this to all age categories we have an adjusted total YLL which is expressed relative to adjusted PYLL.

Table 4 shows the rankings of countries from high to low in terms of these mortality metrics, while table 5 provides the Spearman rank correlations. Simple eye-balling of table 4 suggests that the rankings are very similar and this is confirmed by the correlations in table 5, all of which are above 0.95 and highly significant. The message is fairly clear. No matter which of these mortality metrics is used, the rankings are very similar.

---

<sup>11</sup> It is important to note that the use of the GBD life table for all countries does impose a degree of standardisation on the data. Almost certainly life expectancy, say at age 65, will differ by country. The GBD life table is based on the lowest observed age specific mortality rates for different age groups for the 204 countries in the GBD study.

## 5. Relationship with GDP and Inequality and Cluster Analysis

In this section we investigate the association between age standardised excess mortality and the level and distribution of GDP per capita.<sup>12</sup> We also apply cluster analysis to see if a typology of country experiences can be identified.

Figures 6a-6c present scatter plots for age adjusted excess mortality and the log of GDP per capita as evaluated in 2019, just before the start of Covid.<sup>13</sup> We also show the “line of best fit” for three different specifications: the first is linear, the second is a linear spline with the knot at the median log GDP per capita value of 10.75, while the final is a quadratic. Figure 6a shows the linear fit. There appears to be a clear, negative, relationship between GDP per capita and excess mortality, and we can see the outliers in this relationship. Bulgaria, Lithuania, Slovakia and the US all underperform in the sense of having higher excess mortality than would be predicted by their GDP per capita. On the other side New Zealand is a clear outlier but Croatia, Greece and Portugal also do “better” than their GDP per capita would predict.

Eye-balling figure 6a the relationship looks as though it may be flattening out as countries get richer and so figures 6b and 6c show alternative specifications. In figure 6b we have a linear spline with the knot at median GDP per capita (New Zealand). The negative relationship for countries with below median GDP per capita remains and it now looks as though there is a slight positive relationship for the richer countries. However this is very much driven by the outlier which is the US. For other countries with above median GDP per capita there is effectively no relationship between excess mortality and GDP per capita. Figure 6c is the quadratic specification and is qualitatively very similar to the linear spline. Apart from the US, the relationship between excess mortality and GDP per capita is weak for the richer countries.

The importance of adjusting for age can be seen by comparing figure 6a and figure 6d. In 6d we reproduce the linear fit scatter plot of figure 6a but this time for crude excess mortality. The relative performance of countries such as Italy, Croatia and Slovakia changes quite

---

<sup>12</sup> Results for other excess mortality metrics are available on request.

<sup>13</sup> GDP per capita figures are obtained from the Penn World tables as provided by Our World in Data and are expressed in international dollars at 2017 prices. See <https://archive.ourworldindata.org/20250805-101640/grapher/gdp-per-capita-penn-world-table.html?tab=table>.

significantly when the age adjustment is made, favourably in the case of Italy and Croatia but unfavourably for Slovakia.

Finally, in figure 7, we show the relationship between age standardised excess mortality and inequality as measured by the Gini coefficient for after tax disposable income (for 2019, as provided by Our World in Data). Again we show the best fit linear regression which appears to indicate a positive relationship between excess mortality and inequality. However this slope is not statistically significant with a p-value of 0.27. It is noticeable though that countries above the regression line and who could be viewed as having a worse excess mortality outcome given their Gini coefficient are former centrally planned east European countries. This raises the possibility that there may be clusterings of countries with similar outcomes for excess mortality and GDP per capita/inequality. We now try to analyse this more formally using hierarchical cluster analysis.

Hierarchical cluster analysis proceeds via a series of successive fusions of the observations into groups (recall each observation is an excess mortality-GDP per capita pair or an excess-mortality-Gini pair). Suppose initially there are  $n$  distinct pairs in the data. The first stage of cluster analysis fuses the two most similar pairs to form  $n-1$  clusters and this process continues. At each stage of the cluster analysis pairs which are most “similar” are fused into a group, with different approaches to fusing depending upon the different ways of defining similarity/distance between groups. In this paper the average-link method is used where the closest two groups are determined by the average (dis)similarity between the observations of the two groups at each step.

Ultimately, the fusion into clusters could proceed until the entire sample has been fused into one group. Hence some form of “stopping rule” is needed. There is little in the way of definitive advice on choice of stopping rule, and a mixture of statistical stopping rules and researcher discretion is usually employed (Everitt et al, 2011). The stopping rules employed here are the Calinski-Harabasz (CH) pseudo F, the Duda-Hart (DH) index and the pseudo T squared index.

Suppose there are  $n$  observations in total and  $k$  clusters. Then the CH index is given by  $CH = \frac{(TSSD - \sum_{i=1}^k SSD_i)/(k-1)}{(\sum_{i=1}^k SSD_i)/(n-k)}$  where  $TSSD$  is the total sum of squared distances, and  $SSD_i$  is the sum of

squared distances within group  $i$ . Effectively this compares the sum of squared distances between the clusters relative to the sum of squared distances within the clusters, adjusting for the number of clusters. If  $CH$  increases monotonically with  $k$  this is indicative of no natural clustering, in a sense there are “too many” clusters. If  $CH$  declines monotonically with  $k$  then again there is no clustering but this time for the opposite reason: there is only one cluster. However, if  $CH$  increases to a maximum at  $k$  and then decrease, this suggests the presence of  $k$  clusters.

The other stopping rule utilized is the Duda-Hart index. Consider the case where we have  $k+1$  and  $k$  clusters and let  $DH = \frac{SSD_{k+1}}{SSD_k}$  represent the sum of squared distances for the data with  $k+1$  clusters relative to the sum of squared distances with  $k$  clusters. As with the CH index, if a maximum at  $k$  is observed, then this suggests  $k$  clusters. Closely related to the DH index is the pseudo T squared index, which is the ratio of the between cluster sum of squares for  $k$  and  $k+1$  to the sum of the within cluster sum of squares of  $k$  and  $k+1$  clusters, adjusted for the number of observations in each cluster. In this case a lower value of the pseudo T squared index indicates the presence of clustering.

In common with other studies in this area subjective judgements on behalf of the researcher are also employed as the stopping rules can sometimes indicate an implausible number of clusters or a number which is not helpful in terms of subsequent analysis (Everitt et al, 2011).

Table 6 gives the values for the stopping rules for the three criteria listed above. Note we present results for excess mortality-GDP per capita and excess mortality-Gini but we do not apply cluster analysis to the three variables together, excess mortality, GDP per capita and the Gini coefficient, simultaneously. This is because our interest lies in trying to identify clusters with respect to excess mortality and the two other variables of interest, GDP per capita and the Gini. Applying the analysis to all three variables simultaneously would also incorporate the relationship between GDP per capita and the Gini which, while an interesting research question in its own right, is not of concern to us here.

The results in table 6 suggest possible clusters of 3 and 4 for excess mortality-GDP per capita and 4 and 5 for excess mortality-Gini. We can also observe this in the respective dendrograms in figures 8a and 8b. Visual inspection of these dendrograms indicate optimal values of 3 and

4 respectively, since this is where the vertical gaps in the dissimilarity measure are greatest, and tables 8a and 8b gives the clusters by country. Checking back to figure 6a, for the excess mortality-GDP clusters, we see that Bulgaria, Lithuania and Slovakia clearly stand out as countries with low GDP per capita and high excess mortality. The next cluster of nine countries again feature those with lower excess mortality and relatively higher GDP per capita but still below median GDP per capita. The remainder consist of countries with either quite low excess mortality and/or GDP per capita around or above the median. This final cluster can include countries with quite diverse experiences e.g. New Zealand has very low excess mortality but median GDP per capita, whereas the US has quite high excess mortality but GDP per capita well above the median.

Finally, figure 7 shows the scatter plot for clustering with the Gini coefficient. The cluster analysis identifies Bulgaria and Lithuania as an outlying group with very high excess mortality and high or medium levels of inequality. A second cluster comprises Israel, Chile and the US, three countries with lower excess mortality but high levels of inequality. There is then a three-group cluster of Czechia, Slovakia and Slovenia, all with very low inequality, though varying levels of excess mortality. The final cluster, comprising 23 countries are effectively a central “bloc” in the scatter diagram with a relatively narrow range of both excess mortality and inequality.

## **6. Conclusion**

This paper has analysed excess mortality over the “Covid period” of January 2020-December 2022 for a selection of countries, the choice of which was determined by data availability. The measure of excess mortality employed, that of Karlinsky and Kobak, was shown to be close to other available measures of excess mortality, excepting the IHME data regarded as a clear outlier. The paper also applied age standardization to the excess mortality series to take account of differing age structures by country. For certain countries (e.g. Italy, Chile and Slovakia) the age standardization exerted a non-trivial influence on the level of excess mortality. However, overall the ranking of countries by excess mortality changed little with the standardization.

Further analysis investigated whether the rankings differed according to age bracket, or to the use of an alternative mortality metric, years of life lost. Leaving aside those in the 0-14 age group, where most mortality happens in the first six months of life, again there was a very high

correlation in the ranking of countries by age-specific excess mortality. This very high correlation also extended to the years of life lost metric, confirming that country rankings of excess mortality, for this selection at least, is highly robust to choice of mortality metric.

The final part of the paper applied hierarchical cluster analysis to investigate if any patterns could be found regarding groups of countries in terms of excess mortality, GDP per capita and the Gini coefficient. It found that in general there was an inverse relationship between excess mortality and GDP per capita, but that this flattened out for GDP per capita above the median. A weakly positive relationship was observed between excess mortality and the Gini coefficient.

The cluster analysis suggests that some of the former communist countries of Europe had similar experiences with respect to high rates of excess mortality and low GDP per capita. In terms of excess mortality and the Gini coefficient the picture was more nuanced, with this group of countries, all of whom had high excess mortality, now further broken down into groups with high and low Gini coefficients. The other groups produced by the cluster analysis were predominantly of relatively higher income advanced economies who had lower excess mortality and generally low Gini coefficients, with Israel, Chile and the US as exceptions.

The main purpose of this paper was to investigate cross-country patterns in various metrics of excess mortality. As such, it can act as a useful precursor to possible supra-national examination of other Covid-related outcomes. The analysis shows that rankings across countries are robust to age adjustment and alternative mortality metrics. It also helps identify which countries are “different” and which countries are “similar”. This offers a valuable starting point for cross-country analysis of countries’ “performance” during the Covid pandemic and hopefully provides insights for future worldwide health shocks.

**Acknowledgements:** I am very grateful to Dmitry Kobak for advice in calculating P-scores and to Cormac Ó Gráda for comments on an earlier draft. The usual disclaimer applies.

## References:

Adelman, Sarah, Mia Charifson, Eunsil Seok, Shilpi S. Mehta-Lee, Sara G. Brubaker, Mengling Liu, and Linda G. Kahn. "State-specific fertility rate changes across the USA following the first two waves of COVID-19." *Human Reproduction* 38, no. 6 (2023): 1202-1212.

Bager, Peter, Jens Nielsen, Samir Bhatt, Lise Birk Nielsen, Tyra Grove Krause, and Lasse Skaftø Vestergaard. "Conflicting COVID-19 excess mortality estimates." *The Lancet* 401, no. 10375 (2023): 432-433.

Barbieri, Magali, John R. Wilmoth, Vladimir M. Shkolnikov, Dana Gleit, Domantas Jasilionis, Dmitri Jdanov, Carl Boe, Timothy Riffe, Pavel Grigoriev, and Celeste Winant. "Data resource profile: the human mortality database (HMD)." *International journal of epidemiology* 44, no. 5 (2015): 1549-1556.

Everitt, B.S., Landau, S., Leese, M. & Stahl, D. (2011). *Cluster Analysis*. 5th ed. Wiley Publishing, West Sussex, UK.

Faust, Jeremy Samuel, Harlan M. Krumholz, Chengang Du, Katherine Dickerson Mayes, Zhenqiu Lin, Cleavon Gilman, and Rochelle P. Walensky. "All-cause excess mortality and COVID-19–related mortality among US adults aged 25-44 years, March-July 2020." *JAMA*, 325, no. 8 (2021): 785-787.

Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Reference Life Table. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME), 2020.

Hay, Simon I., and Christopher JL Murray. "Conflicting COVID-19 excess mortality estimates—Authors' reply." *The Lancet* 401, no. 10375 (2023): 433-434.

Hastie, T., R. J. Tibshirani, and J. Friedman. 2009. *The Elements of Statistical Learning: Data Mining, Inference, and Prediction*. 2nd ed. New York: Springer.

HMD. Human Mortality Database. Max Planck Institute for Demographic Research (Germany), University of California, Berkeley (USA), and French Institute for Demographic Studies (France). Available at [www.mortality.org](http://www.mortality.org) (data downloaded on various dates in July 2023).

Karlinsky, Ariel, and Dmitry Kobak. "Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset." *Elife* 10 (2021): e69336.

Kung, Stacey, Marjan Doppen, Melissa Black, Tom Hills, and Nethmi Kearns. "Reduced mortality in New Zealand during the COVID-19 pandemic." *The Lancet* 397, no. 10268 (2021): 25.

Li, Zhihui, Omar Karlsson, Rockli Kim, and S. V. Subramanian. "Distribution of under-5 deaths in the neonatal, postneonatal, and childhood periods: a multicountry analysis in 64 low-and middle-income countries." *International Journal for Equity in Health* 20, no. 1 (2021): 109.

Moeti, Matshidiso, Lindiwe Makubalo, Abdou Salam Gueye, Thierno Balde, Humphrey Karamagi, Gordon Awandare, S. M. Thumbi, Feifei Zhang, Francisca Mutapi, and Mark Woolhouse. "Conflicting COVID-19 excess mortality estimates." *The Lancet* 401, no. 10375 (2023): 431.

Msemburi, William, Ariel Karlinsky, Victoria Knutson, Serge Aleshin-Guendel, Somnath Chatterji, and Jon Wakefield. "The WHO estimates of excess mortality associated with the COVID-19 pandemic." *Nature* 613, no. 7942 (2023): 130-137.

Nepomuceno, Marília R., Ilya Klimkin, Dmitri A. Jdanov, Ainhoa Alustiza-Galarza, and Vladimir M. Shkolnikov. "Sensitivity analysis of excess mortality due to the COVID-19 pandemic." *Population and Development Review* 48, no. 2 (2022): 279-302.

Pace, Monica, E. Cayotte, L. Agafitei, T. Zupanic, B. Wojtyniak, and M. Gissler. "Revision of the European Standard Population—Report of Eurostat’s Task Force-2013 Edition." *Luxembourg: Publications Office* (2013).

Pomar, Léo, Guillaume Favre, Claire De Labrusse, Agathe Contier, Michel Boulvain, and David Baud. "Impact of the first wave of the COVID-19 pandemic on birth rates in Europe: a time series analysis in 24 countries." *Human Reproduction* 37, no. 12 (2022): 2921-2931.


Shkolnikov, Vladimir M., Ilya Klimkin, Martin McKee, Dmitri A. Jdanov, Ainhoa Alustiza-Galarza, László Németh, Sergey A. Timonin, Marília R. Nepomuceno, Evgeny M. Andreev, and David A. Leon. "What should be the baseline when calculating excess mortality? New approaches suggest that we have underestimated the impact of the COVID-19 pandemic and previous winter peaks." *SSM-population health* 18 (2022): 101118.

STMF. 2021. Short-Term Mortality Fluctuation Data Series. Human Mortality Database: University of California Berkeley (USA) and Max Planck Institute for Demographic Research (Germany). <https://www.mortality.org>.


United Nations, Department of Economic and Social Affairs, Population Division (2024). *World Population Prospects 2024*, Online Edition.

Wang, Haidong, Katherine R. Paulson, Spencer A. Pease, Stefanie Watson, Haley Comfort, Peng Zheng, Aleksandr Y. Aravkin et al. "Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21." *The Lancet* 399, no. 10334 (2022): 1513-1536.


**Figure 1: Excess Mortality 2020-2021 (per 100k) as Estimated by Different Models**




**Figure 2: K&K Excess Mortality Estimates as Fraction of *The Economist*, 2020-2022**




**Figure 3: Cumulative Excess Mortality per 100K of Population, 2020-2022**




**Figure 4: Age-standardised excess mortality rates per 100k**




**Figure 5: Age-adjusted excess mortality rate versus crude mortality rate**




**Figure 6a: Age-Standardised Excess Mortality versus Log GDP per capita (linear fit)**




**Figure 6b: Age-Standardised Excess Mortality versus Log GDP per capita (linear spline)**




**Figure 6c: Age-Standardised Excess Mortality versus Log GDP per capita (quadratic fit)**




**Figure 6d: Crude Excess Mortality versus Log GDP per capita (linear fit)**




**Figure 7: Age-Standardised Excess Mortality versus Gini Coefficient**



**Figure 8a: Dendrogram for Age Adjusted Excess Mortality and GDP per Capita**



**Figure 8b: Dendrogram for Age Adjusted Excess Mortality and Gini Coefficient**



**Table 1: Rankings by Age-specific Mortality Rates**

<b>0-14</b>	<b>15-64</b>	<b>65-74</b>	<b>75-84</b>	<b>&gt;84</b>	<b>Total</b>
Canada	Lithuania	Bulgaria	Bulgaria	Bulgaria	Bulgaria
Lithuania	Bulgaria	Lithuania	Slovakia	Lithuania	Lithuania
Latvia	Latvia	Latvia	Czechia	Croatia	Croatia
Switz	US	Croatia	Poland	Slovakia	Slovakia
Croatia	Slovakia	Slovakia	Lithuania	Poland	Latvia
Hungary	Hungary	Hungary	Chile	Chile	Czechia
Sweden	Chile	Poland	Croatia	Germany	Hungary
US	Czechia	US	Hungary	Italy	Italy
Denmark	Poland	Chile	Belgium	Israel	Poland
Spain	Croatia	Germany	US	Switz	US
UK	Greece	Czechia	Greece	S Korea	Greece
S Korea	Canada	Austria	Netherlands	UK	Chile
Netherlands	UK	Italy	Spain	Portugal	Portugal
Greece	Slovenia	Slovenia	Italy	Greece	Spain
Slovakia	Italy	S Korea	Latvia	Czechia	Slovenia
France	Belgium	Greece	UK	Slovenia	UK
Germany	Austria	Spain	Austria	US	Austria
Austria	Spain	Portugal	Slovenia	Spain	Belgium
Italy	Portugal	UK	Israel	Netherlands	Netherlands
Bulgaria	Germany	Belgium	Portugal	Latvia	Germany
Norway	Netherlands	Netherlands	Finland	Finland	Switz
Israel	Finland	Canada	France	France	Finland
Finland	Sweden	Israel	Sweden	Sweden	France
Australia	Switz	Switz	Norway	Norway	Sweden
Slovenia	Israel	France	Canada	Belgium	Canada
Poland	France	Australia	Switz	Austria	Israel
NZ	Norway	Finland	Australia	Australia	S Korea
Portugal	Denmark	NZ	Denmark	Hungary	Norway
Czechia	S Korea	Sweden	NZ	Denmark	Australia
Chile	Australia	Norway	S Korea	Canada	Denmark
Belgium	NZ	Denmark	Germany	NZ	NZ

**Table 2: Spearman Correlations between age-specific mortality rates**

	<b>Total</b>	<b>0-14</b>	<b>15-64</b>	<b>65-74</b>	<b>75-84</b>	<b>&gt;85</b>
<b>Total</b>	1.000					
<b>0-14</b>	0.128	1.000				
<b>15-64</b>	0.911***	0.205	1.000			
<b>65-74</b>	0.894***	0.146	0.862***	1.000		
<b>75-84</b>	0.867***	-0.082	0.834***	0.721***	1.000	
<b>&gt;85</b>	0.616***	-0.020	0.470***	0.631***	0.497***	1.000

**Table 3: GBD Life Table**

<b>Age</b>	<b>Life Expectancy</b>
15	74.07
65	25.68
75	17.10
85	9.99
>85	7.62

**Table 4: Rankings by Age-specific Mortality Rates**

<b>Excess Mortality</b>	<b>Age Adjusted Excess Mortality</b>	<b>YLL</b>	<b>Age adjusted YLL</b>
Bulgaria	Bulgaria	Bulgaria	Bulgaria
Lithuania	Lithuania	Lithuania	Lithuania
Croatia	Slovakia	Latvia	Slovakia
Slovakia	Poland	Croatia	Latvia
Latvia	Latvia	Slovakia	Croatia
Czechia	Czechia	Hungary	US
Hungary	Chile	Poland	Poland
Italy	US	US	Hungary
Poland	Hungary	Czechia	Chile
US	Italy	Italy	Czechia
Greece	Croatia	Greece	Greece
Chile	Greece	Chile	Italy
Portugal	Slovenia	Slovenia	Slovenia
Spain	UK	Austria	UK
Slovenia	Spain	Spain	Austria
UK	Austria	Portugal	Spain
Austria	Portugal	UK	Portugal
Belgium	Belgium	Germany	Canada
Netherlands	Netherlands	Netherlands	Belgium
Germany	Israel	Belgium	Netherlands
Switzerland	Switzerland	Canada	Germany
Finland	Germany	Switzerland	Israel
France	Finland	Finland	Switzerland
Sweden	Canada	France	Finland
Canada	France	Sweden	S Korea
Israel	S Korea	S Korea	Sweden
S Korea	Sweden	Israel	France
Norway	Norway	Norway	Norway
Australia	Australia	Australia	Australia
Denmark	Denmark	Denmark	Denmark
NZ	NZ	NZ	NZ

**Table 5: Spearman Correlations Mortality Metrics**

	<b>Excess Mortality</b>	<b>Age Adjusted Excess Mortality</b>	<b>YLL</b>	<b>Age adjusted YLL</b>
<b>Excess Mortality</b>	1.000			
<b>Age Adjusted Excess Mortality</b>	0.9561***	1.000		
<b>YLL</b>	0.9835***	0.9567***	1.000	
<b>Age adjusted YLL</b>	0.9597***	0.9723***	0.9802***	1.000

**Table 6: Hierarchical Cluster Analysis – Stopping Rule Values**

<b>Clusters</b>	<b>Age Standardised Excess Mortality and GDP per Capita</b>			<b>Age Standardised Excess Mortality and Gini</b>		
	<b>Calinski Harabasz</b>	<b>Duda Hart</b>	<b>Pseudo T Squared</b>	<b>Calinski Harabasz</b>	<b>Duda Hart</b>	<b>Pseudo T Squared</b>
<b>2</b>	19.12	0.4004	38.93	12.22	0.6432	14.98
<b>3</b>	40.29	0.5792	12.35	16.64	0.6257	14.35
<b>4</b>	39.51	0.1863	4.37	21.18	0.6667	10.5
<b>5</b>	33.36	0.0411	23.34	23.02	0.2172	3.6
<b>6</b>	30.41	0.7713	4.15	20.53	0.8341	3.58
<b>7</b>	28.35	0.5166	6.55	19.33	0.0724	12.8

**Table 7a: Cluster Membership, Age Standardised Excess Mortality and GDP per Capita**

<b>Cluster</b>	<b>Countries</b>
<b>1</b>	Australia, Austria, Belgium, Canada, Finland, France, Germany, Israel, Italy, New Zealand, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, UK, US
<b>2</b>	Chile, Croatia, Czechia, Greece, Hungary, Latvia, Poland, Portugal, Slovenia
<b>3</b>	Bulgaria, Lithuania, Slovakia

**Table 7b: Cluster Membership, Age Standardised Excess Mortality and Gini Coefficient**

<b>Cluster</b>	<b>Countries</b>
<b>1</b>	Australia, Austria, Belgium, Canada, Croatia, Finland, France, Germany, Greece, Hungary, Italy, Latvia, New Zealand, Netherlands, Norway, Poland, Portugal, South Korea, Spain, Sweden, Switzerland, UK
<b>2</b>	Czechia, Slovakia, Slovenia
<b>3</b>	US, Israel, Chile
<b>4</b>	Bulgaria, Lithuania



UCD CENTRE FOR ECONOMIC RESEARCH – RECENT WORKING PAPERS  
SRAITH PÁIPÉAR OIBRE AN IONAIÐ UM THAIGHDE EACNAMAÍOCHTA COBÁC

- [WP25/01](#) Judith M. Delaney, Paul J. Devereux: 'Levelling the Playing Field? SES Differences in Graduate Degree Choices' February 2025
- [WP25/02](#) Zilong Li: 'International and Domestic Border Effects in China: Multilateral Resistances, Trade Substitution Patterns and Linguistic Differences' March 2025
- [WP25/03](#) Karl Whelan: 'The Gambler's Ruin with Asymmetric Payoffs' March 2025
- [WP25/04](#) David Madden: 'What Factors Are Associated with the Decline in Young People's Mental Health During the Early Stages of the Covid Pandemic?' March 2025
- [WP25/05](#) Zilong Li: 'Home Bias in Trade within China: The Role of Trust' March 2025
- [WP25/06](#) Bing Guo, Sarah Parlane, Lisa Ryan: 'Regulatory Compliance in the Automobile Industry' March 2025
- [WP25/07](#) Zhiyong Huang, Fabrice Kämpfen: 'Do Health Check-Ups for Seniors Improve Diagnosis and Management of Hypertension and Diabetes in China?' April 2025
- [WP25/08](#) Bernardo S. Buarque, Ronald B. Davies, Ryan M. Hynes, Gianluca Tarasconi, Dieter F. Kogler: 'The Uneven Regional Geography of Telecommunication Standard Essential Patents' April 2025
- [WP25/09](#) Ronald B. Davies: 'Deriving the Trump Tariffs' April 2025
- [WP25/10](#) Ciarán Mac Domhnaill, Lisa Ryan, Ewa Lazarczyk: 'When markets merge: evidence from Ireland's integration with the European wholesale electricity market' April 2025
- [WP25/11](#) Sara Amoroso, Ronald B. Davies: 'M&As and Innovation: A New Approach to Classifying Technology' April 2025
- [WP25/12](#) Margaret Samahita, Martina Zanella: 'Confident, but undervalued: evidence from the Irish Economic Association Conference' April 2025
- [WP25/13](#) Xidong Guo, Zilong Li, Zuzanna Studnicka, Jiming Zhu: 'Environmental Unfamiliarity and Work Performance: Evidence from Chinese Basketball during COVID-19' June 2025
- [WP25/14](#) Ronald B. Davies, Gianluca Santoni, Farid Toubal, Giulio Vannelli: 'Multinational Network, Innovation and the Growth of Employment' July 2025
- [WP25/15](#) Patrick Honohan, Cormac Ó Gráda: 'PETER NEARY James Peter Neary 11 February 1950 –16 June 2021' June 2025
- [WP25/16](#) Ronald B. Davies, Mahdi Ghodsi, Francesca Guadagno: 'Innovation interactions: multinational spillovers and local absorptive capacity' June 2025
- [WP25/17](#) Yota D. Deli, Manthos D. Delis, Adele Whelan: 'Education and Credit' June 2025
- [WP25/18](#) Yota Deli, Manthos D. Delis, Iftekhar Hasan, Panagiotis N. Politsidis, Anthony Saunders: 'Corporate tax changes and credit costs' July 2025
- [WP25/19](#) Constantin Bürgi, Wanying Deng, Karl Whelan: 'Makers and Takers: The Economics of the Kalshi Prediction Market' July 2025
- [WP25/20](#) Chiara Castelli, Ronald B. Davies, Mahdi Ghodsi, Javier Flórez Mendoza: 'Drivers of Foreign Direct Investment in the EU: Regulatory Distance and Revealed Technological Advantage' July 2025
- [WP25/21](#) David Madden: 'Mental Health Resilience During the Covid Pandemic: Evidence from a Sample of Irish Women' August 2025
- [WP25/22](#) Karl Whelan: 'Agreeing to Disagree: The Economics of Betting Exchanges' September 2025
- [WP25/23](#) Ronald B. Davies: 'Innovation and Emissions in Europe' September 2025
- [WP25/24](#) Karl Whelan: 'Ambiguity and the Variance of Gambles' October 2025
- [WP25/25](#) Alan de Bromhead, Ronan C. Lyons, Johann Ohler: 'Build Better Health: Evidence from Ireland on Housing Quality and Mortality' October 2025